Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-538 SAD and MAD in Healthy Participants
NCT07535099Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ICP-538 (4 arms), sponsored by InnoCare Pharma. Primary endpoints: Treatment-emergent adverse events up to 7 weeks, Incidence and severity of abnormal clinical laboratory tests up to 7 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
ICP-538
Beyond the preview
Go deeper on NCT07535099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535099.